GlassScriptPhysician profile
Joan N Meehan
NPI 1437111341
$8,861.44
in general payments reported to CMS, 2019-2025
47 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $577 · 2021: $1,464 · 2022: $1,706 · 2023: $1,679 · 2024: $1,675 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,875 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,874.73 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,546.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,019.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,008.05 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $590.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.49 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $426.81 | 2019-2024 | Arexvy, Shingrix |
| Pfizer INC. | $418.96 | 2019-2025 | |
| Amgen INC. | $399.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Bausch Health US, LLC | $372.19 | 2019-2025 | Aplenzin, Wellbutrin |
| Astellas Pharma US INC | $279.32 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $209.06 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $184.18 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $178.56 | 2019-2022 | |
| Amarin Pharma, INC. | $132.80 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $119.85 | 2022-2024 | Quviviq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.78 | 2019-2024 | Trintellix |
| Exact Sciences Corporation | $101.09 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $87.77 | 2019-2025 | Spravato |
| Currax Pharmaceuticals LLC | $84.04 | 2021-2023 | Nexletol, Contrave, Nexlizet |
| Vivus LLC | $78.85 | 2022-2024 | Qsymia |
| Daiichi Sankyo INC. | $71.28 | 2020-2022 | |
| Medtronic, INC. | $70.26 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Esperion Therapeutics, INC. | $69.87 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $67.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $57.74 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $57.14 | 2020-2021 | |
| Allergan, INC. | $51.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $48.82 | 2024 | Rexulti |
| Corium, LLC | $47.02 | 2022-2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $42.99 | 2019-2023 | Ajovy |
| Abbott Laboratories | $40.15 | 2023-2025 | Eterna, Proclaim |
| Genentech USA, INC. | $36.28 | 2019-2021 | |
| Eisai INC. | $28.86 | 2019 | |
| Sanofi Pasteur INC. | $27.72 | 2019-2021 | |
| Organogenesis INC. | $27.70 | 2022 | |
| Agios Pharmaceuticals, INC. | $21.57 | 2023 | Pyrukynd |
| Boston Scientific Corporation | $20.47 | 2022 | |
| Sumitomo Pharma America, INC. | $20.35 | 2024 | Gemtesa |
| Sonex Health, INC. | $19.05 | 2023 | Sx-One Microknife |
| Jazz Pharmaceuticals INC. | $18.52 | 2021 | |
| Dexcom, INC. | $16.45 | 2024 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $15.63 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.54 | 2022 | |
| Medtronic USA, INC. | $13.45 | 2019 | |
| Organon LLC | $12.25 | 2023 | Renflexis |
| Therapeuticsmd, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Meehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.